Quick Answer
GYRE THERAPEUTICS, INC. reported Diluted EPS of $0.02 per share for fiscal year 2025.
GYRE THERAPEUTICS, INC. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | $0.02 | -60.0% |
| 2024 | $0.05 | +103.5% |
| 2023 | -$1.41 | -4800.0% |
| 2022 | $0.03 | +101.0% |
| 2021 | -$2.87 | -1266.7% |
| 2012 | -$0.21 | +22.2% |
| 2011 | -$0.27 | -175.0% |
| 2010 | $0.36 | +123.4% |
| 2009 | -$1.54 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $0.03 | +200.0% | — |
| June 30, 2025 | $0.00 | -100.0% | — |
| March 31, 2025 | $0.00 | -100.0% | -100.0% |
| September 30, 2024 | $0.01 | -80.0% | +0.0% |
| June 30, 2024 | $0.01 | -50.0% | -66.7% |
| March 31, 2024 | $0.03 | +0.0% | -40.0% |
| September 30, 2023 | $0.05 | +131.2% | +150.0% |
| June 30, 2023 | $0.02 | -98.8% | -33.3% |
- GYRE THERAPEUTICS, INC. showed a decrease of -60.0% in Diluted EPS compared to the prior fiscal year.
- Over the 2009–2025 period, GYRE THERAPEUTICS, INC.’s diluted eps has grown by 101.3% (from $1.54 per share (loss) to $0.02 per share).
- The most recent figure is from GYRE THERAPEUTICS, INC.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 13, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: